Athena Athena

X

Find Drugs in Development News & Deals for Infliximab

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

0

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES

0

DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Details:

Remsima (infliximab) blocks the action of TNF-alpha. It is approved for maintenance therapy in adults with moderately to severely active ulcerative colitis and crohn’s disease.


Lead Product(s): Infliximab

Therapeutic Area: Gastroenterology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

CT-P13 SC is the world’s first subcutaneous formulation of infliximab. A 120 mg fixed dose of CT-P13 SC has been approved for use in the European Union (EU), in adults regardless of body weight, in both existing and newly added indications.


Lead Product(s): Infliximab

Therapeutic Area: Gastroenterology Product Name: Remsima

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 22, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under a prior Memorandum of Understanding, the anti-TNF infliximab, Remsima (a biosimilar of Remicade), approved for use in the U.K., will be supplied for trial by Celltrion Healthcare UK Limited. The University of Oxford and Celltrion are currently completing contract terms.


Lead Product(s): Infliximab

Therapeutic Area: Neurology Product Name: Remsima

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: National Institute for Health and Care Research

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Funding July 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.


Lead Product(s): Infliximab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: SGS Life Sciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Results Remsima (infliximab), showed a statistically significant difference in favour of SC compared to IV-treated patients at week 30 in almost all clinical variables, including low disease activity rates and remission rate.


Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Data from the RTDM study show infliximab drug levels are stable across a 14-day treatment cycle for Crohn’s disease patients in remission, under maintenance therapy with Remsima SC, enabling therapeutic drug monitoring to be performed at any time between the two SC injections.


Lead Product(s): Infliximab

Therapeutic Area: Gastroenterology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 18, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the MOU with Celltrion Healthcare, supply of anti-TNF biosimilar drug used in the ongoing development for new indications including the first antibody biosimilar, Remsima®, infliximab for major autoimmune disorders such as rheumatoid arthritis and ulcerative colitis.


Lead Product(s): Infliximab

Therapeutic Area: Musculoskeletal Product Name: Remsima

Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Celltrion

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement September 20, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Remsima™ SC is the first and only subcutaneous form of infliximab to patients, payers and clinicians in Canada. Remsima™ SC offers an innovative treatment option for patients living with chronic inflammatory conditions in Canada.


Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 07, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The recommended new posology is to start Remsima® SC 120mg weekly up to week 4 and inject every 2 weeks thereafter; For patients currently on infliximab IV, Remsima® SC can be administered after 8 weeks from last dose without additional IV loading.


Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 31, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The three drugs are Janssen’s infliximab (Remicade), Bristol Myers Squibb’s (BMS) abatacept (Orencia) and AbbVie’s investigational late-stage drug Cenicriviroc (CVC).


Lead Product(s): Infliximab,Abatacept,Cenicriviroc

Therapeutic Area: Infections and Infectious Diseases Product Name: Remicade

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 16, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The positive CHMP opinion recommends expanding the marketing authorisation for the subcutaneous (SC) formulation of Remsima® for use in an additional five indications, including for the treatment of inflammatory bowel disease (IBD) and ankylosing spondylitis.


Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 28, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

1-year data from a randomised controlled trial in patients with rheumatoid arthritis (RA) show no impact of body mass index (BMI) on clinical response to subcutaneous infliximab (Remsima® SC / CT-P13 SC).


Lead Product(s): Infliximab

Therapeutic Area: Immunology Product Name: Remsima

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The results from a randomised controlled trial showed that the subcutaneous formulation of infliximab was comparable to the intravenous formulation of CT-P13 in terms of efficacy and safety.


Lead Product(s): Infliximab

Therapeutic Area: Gastroenterology Product Name: Undisclosed

Highest Development Status: Phase IIIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 14, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY